The number of catalysts on the horizon and consistent revenue growth make this an exciting position. I'm glad I've held onto every share.

Never mind, I had dates confused. For some reason thought it was today.

Here is the link to the recording for anyone that wants to watch it. I think Larry foreshadows being close to another acquisition.

https://us06web.zoom.us/webinar/register/WN_chEv1Lu6TBqcue43ikU-qw

Was the investor conference today?

73.9% Gross Margins. That's the most encouraging stat besides the topline revenue growth with pulsevet.

Big day tomorrow. What is everyone's prediction on RS?

I’m sorry you didn’t like my flippant response. Clearly, you can’t expect to be taken seriously when you’re posting nonsensically.

1. The SEC has taken no such action towards social media. No formal policy exists or has been enforced.
2. The random musing regarding the OTC is misplaced, may be better suited for an OTC board.

Make sure you stretch before you reach so hard...

Time to be greedy. Load the boats.

Raise more money to buy back stock and still vote on a reverse split. Certainly, an interesting approach when you already have $50+M cash on hand. The only signal that sends is a big FU to investors.

Are there any catalysts here?

Well Hell yes. Pulsevet Revenue out $8.5M through September 30th, 2021 on pace to deliver around $11.3M annualized or 65% growth over 2020. With some positive news on additional assays we are ready to Pop. Looking forward to 2022.

At these prices and with $54M cash on hand PULM should buy back half the float.

Comments on a post from 3 months ago and calls it outdated. Lol.

Insiders buying they know it's undervalued.

Keep dreaming. Zomedica is about to close another acquisition. The fantasy of an RS is only a shorts-wet dream. Do your homework know what you own.

Does anyone have any insight into what $zom is planning for its SECOND acquisition?

Adios move on troll.

Good lord dark pool is above 60% again. We might see $45 if WSB jumps back on this ticker, to no credit of management.

Short Interest 30,860,436 shares - source: NASDAQ
Short Interest Ratio 4.62 Days to Cover
Short Interest % Float 18.97% - source: NASDAQ (short interest), Capital IQ (float)
Dark Pool Short Volume 4,720,884 shares - source: FINRA
Dark Pool Short Volume Ratio 62.01% - source: FINRA

Howard nothing personal, I suspect you're correct on earnings but hope you're wrong on $3.50. Maybe we get lucky and they announce a new contract and the price goes to $33.50.

I like the way you think.

A2z You've said over and over you closed your position, so why troll?

Positive P/E is just around the corner.

Adding on the marketing

Excellent summary. Thank you for taking the time to consolidate all that information. Someone should make your post sticky.

Has PULM done an RS in the past? I've only been in this position for about 12 months.

There we go. News we were all waiting for, failure to meet the minimum listing price of $1.00. 6 months to regain compliance I expect we'll see a wave of communication from an otherwise dead PR department. I'm doubling down.

11 Reasons, Why I believe Zomedica is a candidate to be acquired by year-end:

1. CEO has stopped defending the share price. The majority of his compensation is in stock.
2. Stephanie Morley stepped down but is onboard as a consultant.
3. Robert Cohen announced his retirement for year-end.
4. Significant institutional investment made at $1.90 per share.
5. Conservation of cash for last 6 months
6. Approval of ZM-17 and ZM-22 patents are imminent
7. They've pulled the pipeline from the website
8. Overly bearish social media presence
9. Hiring of Greg Blair
10. Idexx, Heska, and Elanco are known for buying disrupters.
11. Robert Cohen has made his career of taking early-stage companies through commercialization then selling the company or product line. He was brought in for a reason.

And for the list of reasons, I am Bullish on ZOM

Check out the LinkedIn page of Stephanie Morley. This post was tied to the announcement of Greg Blair back in May. I think she's telling us something is in the works.

I am so proud of the Zomedica team and all they have accomplished in these past 6 years. I have recently transitioned into the role of consultant to Zomedica and am excited for what’s to come!

“I had a vision of establishing a veterinarian-focused company and bringing innovations to the pet health industry in parallel to their entrance into the human medical field,” said Dr. Morley. “I feel a great sense of accomplishment now that TRUFORMA® is commercially available, and I look forward to its continued growth and success.”

Zomedica is hiring again. Accounts receivable clerk and a controller. Great to see they have revenue.

The annual shareholder meeting was a complete waste of time. Nothing material was shared, no questions outside of the items open for a vote were entertained.

Posting here for easy access if anyone is looking to join live in the morning.

The Meeting will be held on Friday, July 30, 2021 at 8:30 a.m. (Toronto time). The Corporation is holding the Meeting as a completely virtual meeting, which will be conducted via live audio cast, where registered shareholders and duly appointed proxyholders, regardless of geographic location, will have an opportunity to participate at the Meeting. Shareholders will not be able to attend the Meeting in person. Registered shareholders and duly appointed proxyholders will be able to attend and participate at the Meeting online at https://web.lumiagm.com/117118024, password "zomedica2021".

Annual Meeting is Friday July 30th

Chucky Schumer to introduce the federal marijuana decriminalization bill by tomorrow. Look for a nice jump in weedstocks.

Cohen is 62, almost 63 years old, came out of retirement for Zomedica. I think he got the company back on track, and he's looking to hand over the reins on the day-to-day. I never thought he would be long-term when he came in last summer. Did you?

There's something big brewing it's been too quiet.

The last time $ZOM barcoded, it ran to three bucks a few days later.

Volume isn't there

Read the 5/17 press release then ask yourself the question. Raised a question that isn't hype.

My thought you have a founding team member leaving yet retaining all equity and being retained as a consultant. Seems like they are clearing the way for an acquisition or to be acquired.

Tell me why I am wrong?

Buyout on the horizon for 2021? :)

The patent decision is due soon on ZM-020, Zomedicas pathogen testing platform. It will be interesting to see if they pull in the commercialization date. Every pet in the US that visits the vet receives a fecal test at least annually.